Epistem Signs Tuberculosis Channel Partner Agreement
News Mar 06, 2012
Epistem has announced the signing of a sales and marketing agreement for its rapid molecular test for Tuberculosis (TB) with Xcelris Labs, one of India’s leading Genomics research and Diagnostic testing companies.
Following the completion of clinical testing, Epistem will prepare regulatory submissions in advance of the launch of its first molecular TB test including patient assessment for antibiotic resistance using its novel Genedrive™ platform.
Genedrive™ provides a major advance in next generation molecular diagnostic testing. It provides a rapid (less than 30 minutes), low cost, simple to use ‘Point of Care’ device with high sensitivity and DNA specificity.
This is applicable to a wide range of viral, bacterial, fungal and somatic mutation disease areas.
Genedrive™ will be targeted at providing the ‘gold standard’ for TB identification and antibiotic resistance testing and will be priced competitively with existing less accurate and slower methods of diagnosis such as microscopy and culturing.
The World Health Organization(WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.
Designed as a handheld device, Genedrive™ brings a new and disruptive approach to diagnostic testing across a broad spectrum of infectious diseases such as TB, Dengue Fever, HIV and a wide range of sexually transmitted diseases (STD’s).
India has the largest number of TB sufferers in the world, more than twice the number in China, which has the second highest infection rate.
According to the WHO, every year 2 million new patients in India develop TB, with the highest incidence of fatalities occurring in remote rural areas.
Xcelris will be the channel partner for distribution of the Genedrive™ technology across India and the Indian sub-continent.
Following regulatory approval, Genedrive™ will be positioned to be included as part of the Indian Revised National TB Control Program(RNTCP).
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018